OMER - Omeros +25% as Medicare OKs pass-through billing status for Omidria

Omeros (OMER) +24.7% post-market after a rule from the Centers for Medicare & Medicaid Services showed the company's Omidria qualifies as a non-opioid pain management drug that functions as a surgical supply.According to Bloomberg, the ruling means Omidria will be excluded from packaging under the ambulatory surgical center payment system for 2021.Omeros' share price has largely discounted a negative outcome for Omidria's reimbursement while assigning minimal value to a successful BLA approval for narsoplimab, Et al BioCapital wrote in a bullish report published on Seeking Alpha.

For further details see:

Omeros +25% as Medicare OKs pass-through billing status for Omidria